Healthcare co-chair and FDA Partner Bryant Godfrey spoke with Bloomberg Law regarding the FDA's scrutiny by federal lawmakers and regulatory attorneys seeking clarity on the agency's authority over social media influencers promoting prescription drugs without clear warnings on the risks. The agency "should issue formal guidance" to "provide a little bit more clarity about who's responsible for what in this case and what FDA touches and what they don't touch," said Bryant Godfrey.
We operate a free-to-view policy, asking only that you register in order to read all of our content. Please login or register to view the rest of this article.